Galapagos NV
Industriepark Mechelen Noord I, Zone L
Generaal De Wittelaan 11 A
Mechelen
B-2800
Tel: 32-15-34-29-00
Fax: 32-15-34-29-01
Website: http://www.galapagosgenomics.com/
606 articles about Galapagos NV
-
Galapagos to host its R&D Update 2022 in New York on 4 November 2022
10/17/2022
Galapagos NV announced that it will host its R&D Day 2022 for analysts, investors and financial press on Friday, 4 November2022.
-
Galapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress
10/6/2022
Galapagos NV (Euronext & NASDAQ: GLPG) will present data at the United European Gastroenterology(UEG)Week2022,taking place from8-11 October 2022. Several Galapagos driven presentationswill be showcased, including new post hoc analyses of the SELECTION study, which investigated the safety and efficacy of Jyseleca®(filgotinib).
-
Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies
10/3/2022
Galapagos NV announced that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company’s Type II variation application for Jyseleca®, a once-daily, oral, JAK1 preferential inhibitor, to amend the European label regarding testicular function after treatment of patients with inflammatory bowel disease and rheumatic conditions.
-
Galapagos to present at upcoming investor conferences - Aug 24, 2022
8/24/2022
Galapagos NV announced that management will participate in the following upcoming investor conferences:
-
Galapagos announced that it had acquired CellPoint and AboundBio in an all-cash transaction, greatly expanding its drug portfolio.
-
Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies
6/21/2022
Galapagos NV (Euronext & NASDAQ: GLPG), CellPoint and AboundBiotoday announced that both companies have entered into definitive agreements with Galapagos, propelling Galapagosinto next-generation cell therapywhile significantly broadening itsportfolio and capabilities.
-
Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress
5/25/2022
Galapagos NV (Euronext & Nasdaq: GLPG) will present 11 abstracts at the European League Against Rheumatism (EULAR) congress 2022, 01-04 June, taking place in Copenhagen, Denmark.
-
Galapagos demonstrates regulatory and commercial progress in Q1 2022
5/5/2022
Galapagos NV announced its first quarter 2022financial results, a year-to-date business updateand its outlook for the remainder of 2022.
-
Galapagos announces appointment of Dr. Paul Stoffels as Chairman of the board
4/26/2022
Galapagos NV announces that theproposed resolutions presented at the extraordinary and annual shareholders’ meetingswere approved, including the implementation of a one-tier governance structure.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Jyseleca® approved in Japan for ulcerative colitis
3/28/2022
Galapagos NV reports that Gilead Sciences K.K., Eisai Co., Ltd. and EA Pharma Co., Ltd. announced the approval by the Japanese Ministry of Health, Labour and Welfare, of a second indication for Jyseleca, a once-daily, oral, JAK1 preferentialinhibitor, for the treatment of patients with moderate-to-severe active ulcerative colitis.
-
Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders’ meetings
3/24/2022
Galapagos NV published its annual report for the financial year 2021 and announces extraordinary and annual shareholders’ meetings to be held sequentially on Tuesday 26 April 2022 at 1:00p.m. and 2:00p.m., respectively, at the registered office of the Company.
-
Galapagos increases share capital through subscription right exercises - Mar 18, 2022
3/18/2022
Galapagos issued 95,500 new ordinary shares on 18 March 2022, for a total capital increase of €2,159,600.00.
-
Galapagos 2021 results set stage for future growth
2/24/2022
Galapagos NV presents financial results 2021, reviews key events forthe company, and provides outlook for 2022.
-
Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohn’s and Colitis Organization (ECCO) annual congress
2/2/2022
Galapagos NV will present data at the European Crohn’s and Colitis Organization annual congress taking place 16-19 February 2022.
-
Galapagos NV has appointed Dr. Paul Stoffelsas as its new chief executive officer, replacing Onno van de Stolpe who is retiring.
-
Galapagos appoints Paul Stoffels as Chief Executive Officer
1/26/2022
Galapagos NV (Euronext & NASDAQ: GLPG) is pleased to announce the appointment of Dr. Paul Stoffelsas Chief Executive Officer (CEO),effective April 1, 2022.
-
JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN
1/18/2022
Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorization for Jyseleca®(filgotinib 200mg tablets), as a new treatment for ulcerative colitis (UC) for Great Britain.
-
Galapagos to present at 40th Annual J.P. Morgan Healthcare Conference
1/6/2022
Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the40th Annual J.P. Morgan Healthcare Conference on January 10-13, 2022.
-
Ryvu announces option to license inflammation program exercised by Galapagos NV
12/14/2021
Ryvu Therapeutics S.A. announced that the pre-agreed criteria in the Option, License and Research Collaboration Agreement, announced between Ryvu and Galapagos on April 16, 2020, have been achieved and Galapagos has exercised its exclusive option for the program.